Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalyn Pharma Inc.AVLN · Entity 4662 | General Counsel | April 29, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalyn Pharma Inc.
Report date April 29, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-28 | Direct | 254,891 |
Reported balance
After 2026-04-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-29 · Grant · Acquired 254,891 · Balance 254,891 F1: 25% of the shares underlying this option vest and become exercisable on April 23, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest and become exercisable on April 23, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed May 4, 2026 10:01 UTC | Avalyn Pharma Inc. AVLN · Entity 4662 | GrantStock Option (Right to Buy) · Derivative | 254,891 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-202381 · ownership.xml · derivative · entry 1 Golden Adam H. · CIK 0002130116 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,891 Underlying: Common Stock · 254,891 shares Expires 2036-04-28 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on April 23, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.